Genomes and Genes
- Development of varicella vaccineMichiaki Takahashi
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
J Infect Dis 197:S41-4. 2008..3%] of 260 vs. 12 [17.1%] of 70, respectively). Because of the pathogenesis of VZV, the incidence of latency and of HZ is predicted to be lower among vaccine recipients than among individuals who have experienced varicella...
- Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblastsKimiyasu Shiraki
Department of Virology, Toyama Medical and Pharmaceutical University, Toyama, Japan
J Infect Dis 188:1875-7. 2003..The high affinity to hepatocytes and lung fibroblasts might correlate with varicella hepatitis and pneumonia and with autopsy observations of varicella. Cell tropism may be important in understanding the pathogenesis of VZV...
- Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assayMichiaki Takahashi
Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan
Vaccine 21:3845-53. 2003..Although this study was uncontrolled open study, the results suggest that administering live varicella vaccine to the elderly is effective for enhancing immunity, particularly CMI to VZV...
- Antibody to varicella-zoster virus immediate-early protein 62 augments allodynia in zoster via brain-derived neurotrophic factorYuka Hama
Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930 0194, Japan
J Virol 84:1616-24. 2010..The intrathecal production of anti-IE62 antibody augmenting BDNF activity and peripheral nerve injury by zoster may participate in the pathogenesis of allodynia in zoster...
- Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virusShigefumi Okamoto
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan
Clin Vaccine Immunol 19:17-22. 2012....
- Varicella-zoster virus ORF 58 gene is dispensable for viral replication in cell cultureHironori Yoshii
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Osaka, Japan
Virol J 5:54. 2008..In order to clarify whether ORF58 is essential for the growth of VZV, we constructed a deletion mutant of ORF58 (pOka-BACDelta58) from the Oka parental genome cloned into a bacterial artificial chromosome (pOka-BAC)...
- DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccineYasuyuki Gomi
Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, 2 9 41, Yahata cho, Kanonji, Kagawa, Japan
Vaccine 26:5627-32. 2008..We also provide evidence that a nonsynonymous substitution at position 105356 may affect viral replication in vivo...
- Effectiveness of live varicella vaccineMichiaki Takahashi
The Research Foundation for Microbial Diseases, Osaka University, Osaka, Japan
Expert Opin Biol Ther 4:199-216. 2004..A clear answer is difficult to give at present, although, for several reasons, such situations may be unlikely to occur...
- Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coliKazuhiro Nagaike
Department of Microbiology, Osaka University Graduate School of Medicine, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
Vaccine 22:4069-74. 2004..The resulting recombinant rV02 grew as well as the parental virus in HEL cells. The recombinant VZV will promote VZV research and increase use of the viral genome as an investigative tool...
- Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatographyTakeshi Tanimoto
Laboratory of Prevention of Viral Disease Research Foundation for Microbial Diseases of Osaka University, Research Institute for Microbial Diseases, Osaka University, 3 1 Yamadaoka, Suita, Osaka 565 0871, Japan
Vaccine 23:4598-609. 2005..4- to 1.6-fold higher than that in the corresponding viral particles. They also suggest that the NA content can be estimated by the immunochoromatography technique using anti-viral NA mAbs...
- Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccinePranee Somboonthum
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7 6 8 Saito Asagi, Ibaraki, Osaka 567 0085, Japan
Vaccine 25:8741-55. 2007..Therefore, the novel varicella vaccine expressing MuV HN protein is suitable as a polyvalent live attenuated vaccine against VZV and MuV infections...
- The molecular epidemiology of varicella-zoster virus: evidence for geographic segregationMark Quinlivan
Department of Medical Microbiology, School of Medicine, Queen Mary College, London, United Kingdom
J Infect Dis 186:888-94. 2002..We used the BglI site to examine both the spread of type A viruses in the United Kingdom and the patterns of VZV infections within persons from different ethnic groups who grew up in the United Kingdom or abroad...
- Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virusYasuyuki Gomi
Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa, Japan
J Virol 76:11447-59. 2002..Furthermore, the Oka vaccine virus was completely distinguishable from P-Oka and 54 clinical isolates by seven restriction-enzyme fragment length polymorphisms that detected differences in the DNA sequence...
- Cloning of full length genome of varicella-zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virusHironori Yoshii
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7 6 8, Saito Asagi, Ibaraki, Osaka 567 0085, Japan
Vaccine 25:5006-12. 2007..This is the first report that the vOka genome was cloned into BAC vector. The rvOka-BAC system would be useful as a vector for construction of recombinant live vaccines...